Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Atara Biotherapeutics, Inc. (ATRA)

Atara Biotherapeutics names interim CFO Kevin Sarney; accounting chief Grant-Huerta departs

Neutral Impact 4 of 5 leadership Written later

Atara Biotherapeutics said its chief accounting officer, Yanina Grant-Huerta, will leave effective July 17, 2026. The board appointed Kevin G. Sarney, a consultant from Charles River CFO, Inc., as interim chief financial officer effective June 26, 2026, and he will also serve as principal accounting officer. The change in its top finance roles is notable for shareholders because it comes through a consulting arrangement rather than a permanent hire.

Key points

  • Yanina Grant-Huerta, Chief Accounting Officer, was notified June 22, 2026 that her employment ends effective July 17, 2026.
  • Kevin G. Sarney appointed interim chief financial officer effective June 26, 2026, serving as principal financial and principal accounting officer.
  • Sarney's services are provided under a consulting agreement with Charles River CFO, Inc.; the Company pays an agreed hourly rate and Sarney receives no direct compensation from the Company.
  • The consulting agreement can be terminated by either party on 30 days written notice.

The filing

CompanyAtara Biotherapeutics, Inc. (ATRA)
Form8-K, current report
Filed with the SECJun 26, 2026, 4:15 PM ET
Accession number0001193125-26-285498

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.